Akari Therapeutics Plc (AKTX) Receivables (2011 - 2013)

Akari Therapeutics (AKTX) has 3 years of Receivables data on file, last reported at $6000.0 in Q4 2013.

• Quarterly Receivables fell 50.0% year-over-year to $6000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $6000.0 (down 50.0% YoY) and the FY2013 annual result came in at $6000.0, down 50.0% from the prior year.
• Receivables eased to $6000.0 in Q4 2013 per AKTX's latest filing, from $12000.0 in the prior quarter.
• The five-year high for Receivables was $19000.0 in Q4 2011, with the low at $6000.0 in Q4 2013.
• Average Receivables over 3 years is $12333.3, with a median of $12000.0 recorded in 2012.
• Year-over-year, Receivables tumbled 36.84% in 2012 and slumped 50.0% in 2013.
• Akari Therapeutics' Receivables stood at $19000.0 in 2011, then slumped by 36.84% to $12000.0 in 2012, then tumbled by 50.0% to $6000.0 in 2013.
• Business Quant data shows AKTX's Receivables at $6000.0 in Q4 2013, $12000.0 in Q4 2012, and $19000.0 in Q4 2011.